GMA-839 is a selective modulator of the γ-aminobutyric acid type A (GABAA) receptor with potent anxiolytic-like activity; it demonstrates significant dose-dependent anxiolytic effects in animal models, is effective at an oral dose of 1.6 mg/kg, and increases punished responding in squirrel monkeys and pigeons; it holds promise for research in the field of anxiolytic therapeutics.